PhageVax Inc Creates (Proposed) Effective Single-dose Vaccine for Novel H1N1 Virus - Commonly Known as the Swine Flu and Now Reported in more than 70 Countries Worldwide
Traditional vaccine generation, using eggs or other cell-culture or other insect-cell media, typically takes from 4 to 6 months. In a time where pandemics can move around the globe at the speed of a jetliner, the ability to develop and manufacture large amounts of vaccine quickly is vital. A key concern is that within the time-frame of traditional vaccine manufacture the pathogen often has mutated, thus rendering the proposed [egg-based or cell-based] vaccines useless. Recent reports from Denmark show that the novel H1N1 was resistant to the anti-viral called Tamiflu. This may become a trend. These various sub-types of Influenza have the potential to merge in the 2nd and 3rd Pandemic Waves and become easily transmissible from human to human.
PhageVax's Bacteriophage-DNA Vaccine Platform represents a "just in time" manufacturing process for combating rapidly evolving infectious diseases. The company's platform technology allows for production of a vaccine (from the initial identification of a pathogen to a cGMP lot of vaccine capable of protecting tens of millions of people) in 4 to 6 weeks; literally in one-quarter the time of traditional methods and at a fraction of the US Tax-payer's cost compared to egg-based Flu Vaccines.
Why is this important? On June 11, the World Health Organization declared a Phase Six global novel H1N1 (swine) Flu Pandemic -with more than 27,000 cases reported in the US alone. A Phase Six pandemic declaration was based upon the sustained worldwide spread of this virus. In addition, it has been learned the deadly H5N1 (avian) virus involved in the Flu outbreaks (in Egypt) is Tamiflu-resistant, although the virus was never exposed to Tamiflu (the primary anti-viral stockpiled against a flu epidemic in the US). The novel H1N1 may merge with the deadly H5N1 from Southeast Asia and/or merge with the deadly H5N1 from Egypt. Each of these H5N1 viruses are distinct from each other, thus raising the complexity of any human protection.
The traditional vaccine production time-frame - especially in terms of flexibility and volume - simply cannot respond quickly enough to combat these unforeseen pathogenic organisms. PhageVax has made arrangements for clinical trials at three research labs to confirm its findings and is currently negotiating with the National Institute of Health, and the CDC and the FDA for implementation and production of vaccines to combat swine flu, avian flu and malaria.
Research suggests that the vaccines may be sufficiently effective where one dose may protect against infection from wild-type disease.
SIGNIFICANT PHAGE ADVANTAGES VIA PhageVax, Inc.
In recent weeks hundreds of people in the US and Mexico may have died from various types of "antibiotic-resistant" bacteria, especially MRSA. In addition, other "antibiotic-resistant" bacteria, such as Salmonella and E. coli are becoming out of control in food, animals and in humans. PhageVax, Inc. is also partnered with US-based companies able to control MRSA and other "antibiotic-resistant" bacteria by applying Bacteriophages.
For further information, please contact Clark Tibbs, CEO, at 740-366-9013 or clark@PhageVax.com
Source: PhageVax Inc
Website: http://phagevax.com/
---
Press release service and press release distribution provided by http://www.24-7pressrelease.com
